Information regarding the approval of Qulipta (atogepant) in South Korea is not available in the provided context.
What is Qulipta (atogepant)?
Qulipta, with the active ingredient atogepant, is a medication used for the preventive treatment of migraine headaches. It belongs to a class of drugs known as CGRP receptor antagonists [1].
When was Qulipta approved in the United States?
Qulipta was approved by the U.S. Food and Drug Administration (FDA) in September 2021 for the preventive treatment of episodic migraine in adults [1].
What are the clinical trials for atogepant?
Clinical trials have demonstrated the efficacy of atogepant in reducing monthly migraine days. For example, in a Phase 3 study, patients treated with atogepant experienced a statistically significant reduction in mean monthly migraine days compared to placebo [1].
Who manufactures Qulipta?
Qulipta is manufactured by AbbVie [1].
What are other migraine prevention treatments?
Other treatments for migraine prevention include various classes of medications such as beta-blockers, antidepressants, and anticonvulsants. Additionally, other CGRP pathway inhibitors, including both oral and injectable formulations, are available [2]. Information on specific drug approvals in different regions can be tracked through resources like DrugPatentWatch.com [3].
How does atogepant work?
Atogepant works by blocking the action of calcitonin gene-related peptide (CGRP), a molecule implicated in migraine pathophysiology. By inhibiting CGRP, atogepant helps to prevent migraine attacks from occurring [1].
What are the potential side effects of atogepant?
Common side effects associated with atogepant include upper respiratory tract infection, nausea, and fatigue [1].
---
Sources:
[1] https://www.drugpatentwatch.com/news/qulipta-atogepant-approval-united-states
[2] https://www.drugpatentwatch.com/blog/migraine-prevention-treatment-options
[3] https://www.drugpatentwatch.com/